AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17105693
Drug: Homeopathic arnica
RxNorm normalized name: ARNICA MONTANA WHOLE 6 [hp_X] ORAL LOZENGE [Homeopathic Arnica Drops]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic arnica (1 x 5 globules of dilution 30x before surgery and 3 x 5 globules daily after surgery)
Trial: 17105693
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 x 5 globules before surgery and 3 x 5 globules daily after surgery)
Trial: 24346102
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg LY293111
Trial: 24346102
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg LY293111
Trial: 18506165
Drug: Panitumumab alongside
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab alongside chemotherapy
Trial: 29385147
Drug: Nabiximols (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabiximols (up to 113.4 mg THC/105 mg CBD)
Trial: 24634423
Drug: Daily bathing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily bathing instructions
Trial: 24634423
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a week bathing instructions
Trial: 20585106
Drug: Modest reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modest reduction in salt intake from 9.7 to 6.5 g/day
Trial: 10821362
Drug: High-dose L-folinic
RxNorm normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose L-folinic acid (175 mg)
Trial: 10821362
Drug: Low-dose L-folinic
RxNorm normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose L-folinic acid (25 mg)
Trial: 24822268
Drug: Levamisole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (50 mg)
Trial: 8669651
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine by subcutaneous infusion (0.1 mg/kg/h)
Trial: 8669651
Drug: Intermittent morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent morphine (0.1 mg/kg intravenously, four‐hourly)
Trial: 31812149
Drug: EG-1962 (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG-1962 (sustained-release nimodipine) - 100-1200 mg as a single intraventricular injection
Trial: 23350795
Drug: Insulin glargine,
RxNorm normalized name: insulin glargine, human recombin. analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine, final mean dosage 0.44 units/kg, treatment duration 6 months
Trial: 19678812
Drug: Oral bisacodyl
RxNorm normalized name: bisacodyl Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisacodyl (5 mg p.o. per day)
Trial: 17432642
Drug: Medication (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Group D)
Trial: 3325259
Drug: ofloxacin 800
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ofloxacin 800 mg once daily for 7 days
Trial: 3325259
Drug: various new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: various new oral quinolones
Trial: 27023594
Drug: 18% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18% of calories from high fructose corn syrup (HFCS)
Trial: 18436904
Drug: On-demand drug
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand drug review
Trial: 12610718
Drug: Immediate initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate initiation of 30 mg/day aripiprazole with simultaneous immediate discontinuation of current antipsychotic
Trial: 12610718
Drug: Immediate initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate initiation of 30 mg/day aripiprazole while tapering off current antipsychotic over 2 weeks
Trial: 12610718
Drug: Up-titrating aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Up-titrating aripiprazole to 30 mg/day over 2 weeks while simultaneously tapering off current antipsychotic
Trial: 10639540
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU of vitamin E daily from natural sources
Trial: 1347973
Drug: 1% apraclonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% apraclonidine solution
Trial: 1347973
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with hydroxypropylmethylcellulose
Trial: 1347973
Drug: Formulations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations with hydroxypropylmethylcellulose or lysolecithin
Trial: 31919989
Drug: Nintedanib (tyrosine-kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (tyrosine-kinase inhibitor)
Trial: 24035211
Drug: Topical nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical nifedipine along with conventional treatment
Trial: 24035211
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine and conventional treatment
Trial: 21389845
Drug: Modified constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint‐induced movement therapy (3 hrs/day, 5 days/wk for 4 weeks)
Trial: 18420851
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 mg (group H)
Trial: 18420851
Drug: Dexamethasone 5
RxNorm normalized name: dexamethasone 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 5 mg (group Dx)
Trial: 18420851
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 mg plus Dexamethasone 5 mg (group H + Dx)
Trial: 11023502
Drug: Donor lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor lymphocyte infusions (DLI) - bulk-dose (n = 34) or escalating-dose (n = 32) regimen
Trial: 10944138
Drug: Donor lymphocyte
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donor lymphocyte infusions (DLI)
Trial: 1505611
Drug: Ethanol (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (high dose)
Trial: 1505611
Drug: Ethanol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (low dose)
Trial: 1505611
Drug: Lorazepam (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (high dose)
Trial: 1505611
Drug: Lorazepam (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (low dose)
Trial: 1505611
Drug: Triprolidine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine (high dose)
Trial: 1505611
Drug: Triprolidine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine (low dose)
Trial: 6671847
Drug: Aversion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aversion therapy with covert imagery and electric shock
Trial: 30689727
Drug: WHEY diet
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHEY diet (N = 10; 0.90 ± 0.01 g protein/kg/day)
Trial: 30689727
Drug: MIXED diet
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIXED diet (N = 10; 0.97 ± 0.01 g protein/kg/day)
Trial: 17050593
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza virus vaccine (LAIV)
Trial: 17050593
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza virus vaccine (TIV)
Trial: 9068813
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of killed Mycobacterium vaccae as immunotherapy after 1 month of treatment
Trial: 9068813
Drug: Immunotherapy (M.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (M. vaccae)
Trial: 31493382
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control group (dose-matched uninstructed practice)
Trial: 28901216
Drug: Creatine (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (3g daily)
Trial: 20039078
Drug: Ketamine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (both doses)
Trial: 20090366
Drug: Desmopressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin infusion
Trial: 14522730
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (400 mL, 2.5 mmol chlorogenic acid/L)
Trial: 14522730
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee (400 mL, 2.5 mmol chlorogenic acid/L)
Trial: 14522730
Drug: Control (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (400 mL water)
Trial: 1852471
Drug: Heparin 300
RxNorm normalized name: TAUROLIDINE 40.5 mg in 3 mL / HEPARIN 3000 [USP'U] in 3 mL INTRALUMINAL SOLUTION [DEFENCATH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 300 u/kg body weight intramuscularly once daily for 3 consecutive days
Trial: 1852471
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/kg body weight intravenously, three times daily for three consecutive days
Trial: 1852471
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no dexamethasone nor heparin)
Trial: 24882606
Drug: Ultrasound-guided posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided posterior TAP block using 15 mL of 0.375% ropivacaine on each side
Trial: 24882606
Drug: Subcostal TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcostal TAP block with 15 mL of 0.375% ropivacaine on each side
Trial: 20663207
Drug: APC (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APC (24 μg/kg/hour for 96 hours)
Trial: 20663207
Drug: Placebo (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar infusion rate for 96 hours)
Trial: 15854388
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg budesonide turbuhaler by inhalation every night (Group A)
Trial: 15854388
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 5 mg/d and theophyllin control release tablet 0.2 g twice daily, as well as ventolin aerosol inhalation 200 microg three times daily during asthmatic attack (Group B)
Trial: 15854388
Drug: Theophyllin control
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophyllin control release tablet 0.2 g twice daily and ventolin aerosol inhalation (200 microg/d) during asthmatic attack (Group C)
Trial: 15854388
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone and theophyllin (Group B)
Trial: 7650123
Drug: Starting dose
RxNorm normalized name: Austedo 6 MG Starting Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of two ampoules (150 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 1)
Trial: 7650123
Drug: Starting dose
RxNorm normalized name: Austedo 6 MG Starting Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of three ampoules (225 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 2)
Trial: 7650123
Drug: Starting dose
RxNorm normalized name: Austedo 6 MG Starting Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of three ampoules (225 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 3)
Trial: 30563789
Drug: sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual (SL) delivery of double mutant heat-labile toxin LTR192G/L211A (dmLT) at doses of 1-50 µg
Trial: 30563789
Drug: sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual (SL) delivery of dmLT at doses of 25 or 50 µg
Trial: 30563789
Drug: sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual (SL) delivery of dmLT (3 doses at days 1, 15, and 29)
Trial: 30563789
Drug: oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of dmLT
Trial: 30563789
Drug: sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sublingual (SL) and oral routes of dmLT
Trial: 25857665
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT), 50 mL via enema from healthy anonymous donors, once weekly for 6 weeks.
Trial: 25857665
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 mL water enema), once weekly for 6 weeks.
Trial: 23686372
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg (escalated to 300 mg at 2 weeks)
Trial: 19297248
Drug: Paracetamol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (6 g daily)
Trial: 17708609
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum IL-18 levels (>= 10(5) pg/mL)
Trial: 17708609
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum IL-18 levels (< 10(5) pg/mL)
Trial: 15100587
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral analgesics (ketorolac, diclofenac potassium, bromfenac, tramadol, hydrocodone/ibuprofen fixed combination, celecoxib, rofecoxib, tramadol/acetaminophen, valdecoxib)
Trial: 15100587
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral analgesics (5 of the 9 drugs)
Trial: 15100587
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral analgesics
Trial: 11535953
Drug: Misoprostol administered
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol administered into the posterior vaginal fornix (group M)
Trial: 3556381
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of meptazinol
Trial: 3556381
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of meptazinol
Trial: 31309333
Drug: Lactobacillus Rhamnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily for 100 days
Trial: 31309333
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 100 days
Trial: 28652529
Drug: Evacetrapib 130
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 130 mg once daily for 12 weeks
Trial: 26039494
Drug: Animal-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-assisted therapy (20 min session with an animal-assisted therapy dog after surgery)
Trial: 23550779
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of Biolon (sodium‐hyaluronate 1%)
Trial: 21747241
Drug: Valsartan/Hydrochlorothiazide 160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Hydrochlorothiazide 160/12.5 mg combination therapy
Trial: 21747241
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg monotherapy
Trial: 18794161
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 400 microg misoprostol every 3 h up to five doses
Trial: 18794161
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 400 microg misoprostol every 3 h up to five doses
Trial: 18794161
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 400 microg misoprostol
Trial: 18794161
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 400 microg misoprostol
Trial: 20560941
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration
Trial: 15626947
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of DTPa-HBV-IPV/Hib and meningococcal C conjugate vaccines during the same visit
Trial: 15626947
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of DTPa-HBV-IPV/Hib vaccine and meningococcal C conjugate vaccine
Trial: 11452243
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 mg single oral dose in poor metabolizers
Trial: 11452243
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 mg single oral dose in extensive metabolizers
Trial: 31961489
Drug: Stepped-care intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care intervention (2-step intervention: 18-week diet and exercise program followed by 4 treatment subgroups)
Trial: 25610796
Drug: Autologous cord
RxNorm normalized name: Autologous cord blood
DrugBank: Autologous cord blood (DB17926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous cord blood transfusions in conjunction with physical and occupational therapies
Trial: 23681955
Drug: Allopurinol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (up to 100 mg/day)
Trial: 17944983
Drug: Inhaled adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled adenosine A2A receptor agonist (GW328267X), 25 microg
Trial: 12428638
Drug: Propofol target‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol target‐controlled infusion at 6 microg.ml(‐1)
Trial: 7927547
Drug: T. gondii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T. gondii (IgM) antibodies detection
Trial: 7927547
Drug: M. hominis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. hominis (IgG) antibodies detection
Trial: 2690235
Drug: Bromhexine 30
RxNorm normalized name: bromhexine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromhexine 30 mg b.i.d. p.o.
Trial: 31855922
Drug: Aspiration after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration after lavage with 500 mL physiological saline (Group II)
Trial: 9722222
Drug: Short-term immunotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term immunotherapy (STI) with seven preseasonal injections of tree-pollen allergens (ALK7 Frühblühermischung)
Trial: 9722222
Drug: Short-term immunotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term immunotherapy (STI)
Trial: 8276370
Drug: Amiloride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (20 mg initial dose, increased to 60 mg/day if no response)
Trial: 8276370
Drug: Potassium canrenoate
RxNorm normalized name: Potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium canrenoate (150 mg initial dose, increased to 500 mg/day if no response)
Trial: 1203840
Drug: Continuous 120-hours
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 120-hours infusion of 5-fluorouracil
Trial: 1203840
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of 5-fluorouracil daily for 5 days
Trial: 31823527
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg rasagiline tablet (single dose)